Anti-Müllerian Hormone in PCOS

A Review Informing International Guidelines

Helena Teede*, Marie Misso, Eliza C. Tassone, Didier Dewailly, Ernest Hy Ng, Ricardo Azziz, Robert J. Norman, Marianne Andersen, Stephen Franks, Kathleen Hoeger, Samantha Hutchison, Sharon Oberfield, Duru Shah, Femke Hohmann, Sasha Ottey, Preeti Dabadghao, Joop S.E. Laven

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

Abstract

Polycystic ovary syndrome (PCOS) affects 8–13% of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-Müllerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.

Original languageEnglish
JournalTrends in Endocrinology and Metabolism
Volume30
Issue number7
Pages (from-to)467-478
ISSN1043-2760
DOIs
Publication statusPublished - 1. Jul 2019

Fingerprint

Polycystic Ovary Syndrome
Hormones
Guidelines
Cluster Analysis
Health
Serum
Research
Population

Keywords

  • adolescent
  • adult
  • anti-Müllerian hormone
  • diagnostic accuracy
  • polycystic ovary syndrome
  • review

Cite this

Teede, H., Misso, M., Tassone, E. C., Dewailly, D., Ng, E. H., Azziz, R., ... Laven, J. S. E. (2019). Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines. Trends in Endocrinology and Metabolism, 30(7), 467-478. https://doi.org/10.1016/j.tem.2019.04.006
Teede, Helena ; Misso, Marie ; Tassone, Eliza C. ; Dewailly, Didier ; Ng, Ernest Hy ; Azziz, Ricardo ; Norman, Robert J. ; Andersen, Marianne ; Franks, Stephen ; Hoeger, Kathleen ; Hutchison, Samantha ; Oberfield, Sharon ; Shah, Duru ; Hohmann, Femke ; Ottey, Sasha ; Dabadghao, Preeti ; Laven, Joop S.E. / Anti-Müllerian Hormone in PCOS : A Review Informing International Guidelines. In: Trends in Endocrinology and Metabolism. 2019 ; Vol. 30, No. 7. pp. 467-478.
@article{544c028ddb8f449281180387930df8e9,
title = "Anti-M{\"u}llerian Hormone in PCOS: A Review Informing International Guidelines",
abstract = "Polycystic ovary syndrome (PCOS) affects 8–13{\%} of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-M{\"u}llerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.",
keywords = "adolescent, adult, anti-M{\"u}llerian hormone, diagnostic accuracy, polycystic ovary syndrome, review",
author = "Helena Teede and Marie Misso and Tassone, {Eliza C.} and Didier Dewailly and Ng, {Ernest Hy} and Ricardo Azziz and Norman, {Robert J.} and Marianne Andersen and Stephen Franks and Kathleen Hoeger and Samantha Hutchison and Sharon Oberfield and Duru Shah and Femke Hohmann and Sasha Ottey and Preeti Dabadghao and Laven, {Joop S.E.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.tem.2019.04.006",
language = "English",
volume = "30",
pages = "467--478",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier",
number = "7",

}

Teede, H, Misso, M, Tassone, EC, Dewailly, D, Ng, EH, Azziz, R, Norman, RJ, Andersen, M, Franks, S, Hoeger, K, Hutchison, S, Oberfield, S, Shah, D, Hohmann, F, Ottey, S, Dabadghao, P & Laven, JSE 2019, 'Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines', Trends in Endocrinology and Metabolism, vol. 30, no. 7, pp. 467-478. https://doi.org/10.1016/j.tem.2019.04.006

Anti-Müllerian Hormone in PCOS : A Review Informing International Guidelines. / Teede, Helena; Misso, Marie; Tassone, Eliza C.; Dewailly, Didier; Ng, Ernest Hy; Azziz, Ricardo; Norman, Robert J.; Andersen, Marianne; Franks, Stephen; Hoeger, Kathleen; Hutchison, Samantha; Oberfield, Sharon; Shah, Duru; Hohmann, Femke; Ottey, Sasha; Dabadghao, Preeti; Laven, Joop S.E.

In: Trends in Endocrinology and Metabolism, Vol. 30, No. 7, 01.07.2019, p. 467-478.

Research output: Contribution to journalReviewResearchpeer-review

TY - JOUR

T1 - Anti-Müllerian Hormone in PCOS

T2 - A Review Informing International Guidelines

AU - Teede, Helena

AU - Misso, Marie

AU - Tassone, Eliza C.

AU - Dewailly, Didier

AU - Ng, Ernest Hy

AU - Azziz, Ricardo

AU - Norman, Robert J.

AU - Andersen, Marianne

AU - Franks, Stephen

AU - Hoeger, Kathleen

AU - Hutchison, Samantha

AU - Oberfield, Sharon

AU - Shah, Duru

AU - Hohmann, Femke

AU - Ottey, Sasha

AU - Dabadghao, Preeti

AU - Laven, Joop S.E.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Polycystic ovary syndrome (PCOS) affects 8–13% of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-Müllerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.

AB - Polycystic ovary syndrome (PCOS) affects 8–13% of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-Müllerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.

KW - adolescent

KW - adult

KW - anti-Müllerian hormone

KW - diagnostic accuracy

KW - polycystic ovary syndrome

KW - review

U2 - 10.1016/j.tem.2019.04.006

DO - 10.1016/j.tem.2019.04.006

M3 - Review

VL - 30

SP - 467

EP - 478

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

IS - 7

ER -